What changed: label update log

33 ENTRIES · NEWEST FIRST

Reviewed by Tariq Halim, MD · Last medical review: November 12, 2026 · Editorial policy

A dated log of FDA label changes, regulatory events and DailyMed marketing end dates for the ADHD medicines on this site, newest first. Each entry says what changed, links to the product page and cites the label or FDA document. Subscribe with the Atom feed.

Method: label revision dates and Recent Major Changes come from the DailyMed pages read on Oct 29, 2026. When a label was revised but lists no Recent Major Changes, the entry says the specific edits were not identified; no change is inferred. Entries marked “marketing end dates, not a label revision” report the marketing end dates shown in DailyMed product listings (retrieved Oct 29, 2026); they do not mean the label text changed.

Changes

Oct 30, 2026

Simtriyo (centanafadine) placed in DEA Schedule III; now marketable

The DEA published an interim final rule placing centanafadine in Schedule III (CIII), effective the same day: 91 FR 68470, FR Doc. 2026-22208, Docket No. DEA-1743. Public comments are due Nov 30, 2026.

FDA approval of Simtriyo became effective when the rule was published, so Simtriyo can now be marketed. The Prescribing Information revised 10/2026 is labeled CIII. DailyMed (SPL version 1, published Oct 26, 2026) lists a marketing start date of Oct 24, 2026.

No Otsuka launch press release was found and pharmacy stocking was not confirmed as of Nov 4, 2026: check pharmacy availability. There is no generic or authorized generic.

Page: Simtriyo · Source: Federal Register: 91 FR 68470 · Simtriyo Prescribing Information, revised 10/2026 · DailyMed: Simtriyo

Oct 29, 2026 (DailyMed listing checked; marketing end dates, not a label revision)

Ritalin LA (brand): marketing end dates listed on DailyMed

DailyMed’s listing for brand Ritalin LA (Novartis; SPL version 36) shows marketing end dates of Sep 30, 2026 for the 10 mg and 30 mg capsules and Oct 31, 2026 for the 20 mg and 40 mg capsules. These are marketing dates in the product listing, not a change to the label, which is still revised 9/2025.

The Sandoz authorized-generic listing shows its capsules as marketed with no end date. The FDA Orange Book still lists the 10 to 40 mg brand strengths as active (rechecked Oct 29, 2026).

Page: Ritalin LA · Source: DailyMed SPL: Ritalin LA (Novartis), version 36, retrieved Oct 29, 2026 · DailyMed SPL: Sandoz authorized generic, retrieved Oct 29, 2026

Oct 29, 2026 (DailyMed listing checked; marketing end dates, not a label revision)

Mylan generic methylphenidate patch: marketing end dates listed on DailyMed

DailyMed’s listing for Mylan’s generic methylphenidate transdermal system (SPL version 6) shows marketing end dates of Jan 31, 2027 for the 30 mg patch and Apr 30, 2027 for the 10, 15 and 20 mg patches. These are marketing dates in the product listing, not a change to the label.

As of Oct 29, 2026, ASHP lists Mylan (Viatris) patches as available, and the Padagis authorized-generic listing shows no end date.

Page: Daytrana · Source: DailyMed SPL: Mylan methylphenidate transdermal system, version 6, retrieved Oct 29, 2026 · DailyMed SPL: Padagis authorized generic, retrieved Oct 29, 2026

Oct 29, 2026 (DailyMed listing checked; marketing end dates, not a label revision)

Aptensio XR: marketing end date listed on DailyMed; listing dropped from DailyMed search

DailyMed’s listing for brand Aptensio XR (Rhodes; SPL version 17, published May 25, 2026) shows a marketing end date of May 20, 2026 for all seven strengths. This is a marketing date in the product listing, not a change to the label.

On Oct 29, 2026 the listing no longer appeared in DailyMed search results, although its page still opened from a direct link. The FDA Orange Book still lists all seven strengths as active, and ASHP lists the brand and the Rhodes authorized generic on back order.

Page: Aptensio XR · Source: DailyMed SPL: Aptensio XR (Rhodes), version 17, retrieved Oct 29, 2026 · DailyMed search for Aptensio (no results), Oct 29, 2026

Oct 26, 2026

Simtriyo label posted on DailyMed (before DEA scheduling)

DailyMed posted the Simtriyo (centanafadine) label; that version stated that the controlled-substance schedule was pending (the label revised 10/2026 is labeled CIII).

The DEA rule to place centanafadine in Schedule III finished federal (OIRA) review on Oct 22, 2026; it was published on Oct 30, 2026 (see that entry), which made the FDA approval effective.

Page: Simtriyo · Source: DailyMed: Simtriyo · reginfo.gov: OIRA review RIN 1117-ZA11 · Federal Register search: centanafadine

Oct 2026 (label revised 10/2026; DailyMed SPL date Oct 21, 2026)

Metadate CD label revised (Lannett)

Indication is now pediatric patients 6 years and older (previously ages 6 to 15); the label is not indicated for adults.

Alcohol is now listed as a drug interaction (section 7); the Medication Guide’s most common side effects add headache and stomach pain; contraindications are listed in full (Recent Major Changes: Contraindications, 07/2026).

Page: Metadate CD · Source: Metadate CD label (revised 10/2026)

Jul 24, 2026

Simtriyo (centanafadine) approved by FDA

FDA approved Simtriyo (NDA 218145, Otsuka) for ADHD in adults and in children 6 and older who weigh at least 20 kg; label dated 07/2026. Marketing had to wait for DEA scheduling, which took effect Oct 30, 2026 (see that entry).

Page: Simtriyo · Source: FDA approval letter

Jun 2026 (label revised 6/2026; DailyMed SPL date Jun 30, 2026)

Strattera label revised

The label was revised 6/2026 but lists no Recent Major Changes, so the specific edits were not identified for this log.

Page: Strattera (atomoxetine) · Source: Strattera (atomoxetine) label (revised 06/2026)

Apr 2026 (label revised 4/2026; DailyMed SPL date Apr 20, 2026)

Concerta label revised

Dosage sections 2.3 (patients new to methylphenidate) and 2.4 (patients switching from another methylphenidate product) changed in 2/2026.

The warnings on seizures and on periodic hematologic (blood count) monitoring were removed in 2/2026.

Also listed as recent: the 9/2025 Indications change (not recommended under age 6) and the long-term growth suppression warning.

Page: Concerta · Source: Concerta label (revised 04/2026)

April 2026

Vyvanse label revised

Current label revised 4/2026 (DailyMed SPL date April 30, 2026).

Recent Major Changes listed on the label: Indications and Usage (1), 09/2025; Warnings and Precautions (5.5 Long-Term Suppression of Growth in Pediatric Patients), 09/2025.

Page: Vyvanse · Source: Vyvanse label (revised 04/2026)

April 2026

QuilliChew ER label revised

Current label revised 4/2026 (DailyMed SPL date April 8, 2026).

Recent Major Changes listed on the label: Indications and Usage (1), 09/2025; Warnings and Precautions (5.7 Long-Term Suppression of Growth in Pediatric Patients), 09/2025; Dosage Forms and Strengths (3), 03/2026.

Page: QuilliChew ER · Source: QuilliChew ER label (revised 04/2026)

April 2026

Mydayis label revised

Current label revised 4/2026 (DailyMed SPL date April 30, 2026).

The label lists no Recent Major Changes, so the specific edits were not identified for this log.

Page: Mydayis · Source: Mydayis label (revised 04/2026)

April 2026

Adderall XR label revised

Current label revised 4/2026 (DailyMed SPL date April 30, 2026).

Recent Major Changes listed on the label: Indications and Usage (1), 09/2025; Warnings and Precautions (5.5 Long-Term Suppression of Growth in Pediatric Patients), 09/2025.

Page: Adderall XR · Source: Adderall XR label (revised 04/2026)

Mar 20, 2026

Atoncy (atomoxetine oral solution) approved; marketing started

FDA approved Atoncy, a 4 mg/mL atomoxetine oral solution (NDA 220320), on Mar 20, 2026; DailyMed lists Atoncy and an authorized generic with a marketing start of Mar 20, 2026. Current label revised 3/2026 (first DailyMed version effective Apr 2, 2026).

Page: Atoncy · Source: Atoncy label (SPL version 1, effective Apr 2, 2026)

Mar 20, 2026

Arynta marketing started

DailyMed lists a marketing start date of Mar 20, 2026 for Arynta (approved Jun 16, 2025, NDA 219847).

Page: Arynta · Source: FDA approval letter · Arynta label (revised 12/2025)

March 2026

Quillivant XR label revised

Current label revised 3/2026 (DailyMed SPL date March 24, 2026).

Recent Major Changes listed on the label: Dosage Forms and Strengths (3), 03/2026; Indications and Usage (1), 09/2025; Warnings and Precautions (5.7 Long-Term Suppression of Growth in Pediatric Patients), 09/2025.

Page: Quillivant XR · Source: Quillivant XR label (revised 03/2026)

Dec 31, 2025

DEA and HHS extend telemedicine prescribing of controlled medicines through 2026

The DEA, jointly with HHS, published a fourth temporary extension of the COVID-19 telemedicine flexibilities for prescribing controlled medications (90 FR 61301, FR Doc. 2025-24123). It is effective Jan 1, 2026 through Dec 31, 2026.

The flexibilities let practitioners prescribe Schedule II–V controlled medications, which include ADHD stimulants, through audio-video telemedicine visits without the in-person evaluation the Ryan Haight Act otherwise requires, provided the prescriptions meet the other requirements. No further extension had been published in the Federal Register as of Nov 9, 2026.

Pages: Concerta, Focalin XR, Jornay PM, Ritalin LA, Aptensio XR, Quillivant XR, Cotempla XR-ODT, Azstarys, Daytrana, Ritalin, Adhansia XR, QuilliChew ER, Focalin, Relexxii, Metadate CD, Methylin, Methylphenidate ER (10/20 mg), Methylphenidate Chewable, Vyvanse, Adderall XR, Xelstrym, Adderall, Mydayis, Adzenys XR-ODT, Dyanavel XR, Evekeo, Arynta, Zenzedi, ProCentra, Dexedrine Spansule, Evekeo ODT, Desoxyn, Simtriyo · Source: Federal Register: 90 FR 61301

December 2025

Arynta label revised

Current label revised 12/2025 (DailyMed SPL date July 30, 2025).

DailyMed’s SPL effective date is earlier than the revision date printed on the label; both are shown as published.

Recent Major Changes listed on the label: Indications and Usage (1), 09/2025; Warnings and Precautions (5.5 Long-Term Suppression of Growth in Pediatric Patients), 09/2025.

Page: Arynta · Source: Arynta label (revised 12/2025)

October 2025

Methylphenidate ER (10/20 mg) label revised

Current label revised 10/2025 (DailyMed SPL date October 8, 2025).

The label lists no Recent Major Changes, so the specific edits were not identified for this log.

Page: Methylphenidate ER (10/20 mg) · Source: Methylphenidate ER (10/20 mg) label (revised 10/2025)

October 2025

Kapvay label revised

Current label revised 10/2025 (DailyMed SPL date October 31, 2025).

The label lists no Recent Major Changes, so the specific edits were not identified for this log.

Page: Kapvay · Source: Kapvay label (revised 10/2025)

Sep 2025

Stimulant labels: use under age 6 not recommended; growth warning revised

These labels list two Recent Major Changes dated 09/2025: Indications and Usage (section 1) now states that use is not recommended in children younger than 6 because they had higher drug exposure and more side effects (such as weight loss) at the same dose, and the Long-Term Suppression of Growth in Pediatric Patients warning was revised.

Pages: Adderall XR, Adzenys XR-ODT, Aptensio XR, Arynta, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Dyanavel XR, Focalin XR, Jornay PM, QuilliChew ER, Quillivant XR, Relexxii, Ritalin LA, Vyvanse, Xelstrym · Source: each product’s label: see Current label versions below

June 2025

Intuniv label revised

Current label revised 6/2025 (DailyMed SPL date June 23, 2025).

The label lists no Recent Major Changes, so the specific edits were not identified for this log.

Page: Intuniv · Source: Intuniv label (revised 06/2025)

June 2025

Evekeo label revised

Current label revised 06/2025 (DailyMed SPL date October 10, 2025).

The label lists no Recent Major Changes, so the specific edits were not identified for this log.

Page: Evekeo · Source: Evekeo label (revised 06/2025)

May 2025

Zenzedi label revised

Current label revised 05/2025 (DailyMed SPL date November 26, 2025).

The label lists no Recent Major Changes, so the specific edits were not identified for this log.

Page: Zenzedi · Source: Zenzedi label (revised 05/2025)

May 2025

ProCentra label revised

Current label revised 05/2025 (DailyMed SPL date May 14, 2025).

The label lists no Recent Major Changes, so the specific edits were not identified for this log.

Page: ProCentra · Source: ProCentra label (revised 05/2025)

April 2025

Onyda XR label revised

Current label revised 4/2025 (DailyMed SPL date April 11, 2025).

Recent Major Changes listed on the label: Warnings and Precautions (5.3 Rebound Hypertension), 04/2025.

Page: Onyda XR · Source: Onyda XR label (revised 04/2025)

March 2025

Methylphenidate Chewable label revised

Current label revised 3/2025 (DailyMed SPL date March 12, 2025).

The label lists no Recent Major Changes, so the specific edits were not identified for this log.

Page: Methylphenidate Chewable · Source: Methylphenidate Chewable label (revised 03/2025)

February 2025

Ritalin label revised

Current label revised 2/2025 (DailyMed SPL date February 5, 2025).

The label lists no Recent Major Changes, so the specific edits were not identified for this log.

Page: Ritalin · Source: Ritalin label (revised 02/2025)

January 2025

Qelbree label revised

Current label revised 1/2025 (DailyMed SPL date October 5, 2026).

The label lists no Recent Major Changes, so the specific edits were not identified for this log.

Page: Qelbree · Source: Qelbree label (revised 01/2025)

September 2024

Desoxyn label revised

Current label revised 9/2024 (DailyMed SPL date September 30, 2024).

Recent Major Changes listed on the label: Boxed Warning, 10/2023; Dosage and Administration (2.1 Pretreatment Screening), 10/2023; Warnings and Precautions (5.1 Abuse, Misuse, and Addiction; 5.2 Risks to Patients with Serious Cardiac Disease; 5.9 Motor and Verbal Tics, and Worsening of Tourette’s Syndrome), 10/2023.

Page: Desoxyn · Source: Desoxyn label (revised 09/2024)

May 2024

Focalin label revised

Current label revised 5/2024 (DailyMed SPL date May 30, 2024).

Recent Major Changes listed on the label: Boxed Warning, 10/2023; Dosage and Administration (2.1 Pretreatment Screening; 2.2 Recommended Dosage), 10/2023; Warnings and Precautions (5.1 Abuse, Misuse, and Addiction; 5.2 Risks to Patients with Serious Cardiac Disease; 5.8 Acute Angle Closure Glaucoma; 5.9 Increased Intraocular Pressure and Glaucoma; 5.10 Motor and Verbal Tics, and Worsening of Tourette’s Syndrome), 10/2023.

Page: Focalin · Source: Focalin label (revised 05/2024)

November 2023

Methylin label revised

Current label revised 11/2023 (DailyMed SPL date November 1, 2023).

Recent Major Changes listed on the label: Boxed Warning, 10/2023; Dosage and Administration (2.1 Pretreatment Screening; 2.2 General Dosing Information; 2.3 Dosage Reduction and Discontinuation), 10/2023; Warnings and Precautions (5.1 Abuse, Misuse, and Addiction; 5.2 Risks to Patients with Serious Cardiac Disease; 5.8 Acute Angle Closure Glaucoma; 5.9 Increased Intraocular Pressure and Glaucoma; 5.10 Motor and Verbal Tics, and Worsening of Tourette’s Syndrome), 10/2023.

Page: Methylin · Source: Methylin label (revised 11/2023)

June 2021

Adhansia XR label revised

Current label revised 6/2021.

The label lists no Recent Major Changes, so the specific edits were not identified for this log.

Page: Adhansia XR · Source: Adhansia XR label (revised 06/2021)

Current label versions

Revision date printed on each label, and the “Updated” date DailyMed shows for the listing (the SPL effective date), read Oct 29, 2026.

ProductLabel revisedDailyMed SPL dateLink
Concerta4/2026April 20, 2026label
Vyvanse4/2026April 30, 2026label
Adderall XR4/2026April 30, 2026label
Focalin XR9/2025September 23, 2025label
Jornay PM9/2025October 3, 2025label
Ritalin LA9/2025September 23, 2025label
Aptensio XR9/2025—label
Quillivant XR3/2026March 24, 2026label
Cotempla XR-ODT9/2025March 2, 2026label
Azstarys9/2025May 11, 2026label
Daytrana9/2025September 1, 2025label
Xelstrym9/2025December 23, 2025label
Qelbree1/2025October 5, 2026label
Simtriyo7/2026July 31, 2026label
Strattera (atomoxetine)6/2026June 30, 2026label
Intuniv6/2025June 23, 2025label
Kapvay10/2025October 31, 2025label
Ritalin2/2025February 5, 2025label
Adderallnot shownMay 29, 2024label
Mydayis4/2026April 30, 2026label
Adhansia XR6/2021—label
Onyda XR4/2025April 11, 2025label
QuilliChew ER4/2026April 8, 2026label
Focalin5/2024May 30, 2024label
Adzenys XR-ODT9/2025May 13, 2026label
Dyanavel XR9/2025February 24, 2026label
Evekeo06/2025October 10, 2025label
Relexxii9/2025September 26, 2025label
Metadate CD10/2026October 21, 2026label
Arynta12/2025July 30, 2025label
Zenzedi05/2025November 26, 2025label
ProCentra05/2025May 14, 2025label
Dexedrine Spansulenot shownSeptember 25, 2025label
Methylin11/2023November 1, 2023label
Evekeo ODTNo current DailyMed label (discontinued; page uses the Drugs@FDA label, revised 10/2023)label
Desoxyn9/2024September 30, 2024label
Atoncy3/2026April 2, 2026label
Methylphenidate ER (10/20 mg)10/2025October 8, 2025label
Methylphenidate Chewable3/2025March 12, 2025label
EDUCATIONAL INFORMATION ONLY. Not medical advice. Medication decisions require individualized assessment by a qualified clinician. Do not start, stop, switch or change the dose of a medication without your prescriber. See the medical disclaimer.